Wolverine Asset Management’s ProKidney PROK Stock Holding History

Wolverine Asset Management’s Portfolio PROK Stock Details PROK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-19,296	Closed	-$191K	–	2329
2021 Q4	$191K	Sell	19,296 -9,100	-32%	-$90K	﹤0.01%	1235
2021 Q3	$278K	Sell	28,396 -6,604	-19%	-$65K	﹤0.01%	1112
2021 Q2	$353K	Buy	+35,000	New	+$354K	﹤0.01%	1041

Other funds holding PROK

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

ACA

Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Governors Lane New York $1.56B AUM 30.42% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Wolverine Asset Management's PROK Position: Q1 2022 in Review

Wolverine Asset Management sold out of ProKidney (PROK) in Q1 2022, closing a stake of 19,296 shares — an estimated $191K sold.

Wolverine Asset Management first reported a position in PROK in Q2 2021 and held it in 3 quarters. The position peaked at $353K in Q2 2021. 80 funds tracked by Wall St. Rank hold PROK as of Q1 2022.

Wolverine Asset Management reported no remaining ProKidney position as of Q1 2022 after selling out during the quarter.
Wolverine Asset Management sold 19,296 ProKidney shares in Q1 2022, an estimated $191K.
Wolverine Asset Management first reported a position in ProKidney in Q2 2021 and held it in 3 quarters.
Wolverine Asset Management's ProKidney position peaked at $353K in Q2 2021.
80 funds tracked by Wall St. Rank held ProKidney as of Q1 2022.

Based on Wolverine Asset Management's 13F filing for Q1 2022, filed 4 May 2022.